Re: CYP17 promoter polymorphism and breast cancer in Australian women under age forty years [1]

Journal of the National Cancer Institute

Volumn 93, Issue 7, 2001, Pages 554-555

  Jernström, Helena ^a,b   Vesprini, Danny ^a   Bradlow, H Leon ^c   Narod, Steven A ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

^c Strang Cancer Research Laboratory   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

16ALPHA HYDROXYESTRONE; 2 HYDROXYESTRONE; CYTOCHROME P450; ESTRADIOL; ORAL CONTRACEPTIVE AGENT;

ADOLESCENT; ADULT; AGE; AUSTRALIA; BREAST CANCER; CANCER RISK; CONTROLLED STUDY; ESTRADIOL BLOOD LEVEL; FAMILY HISTORY; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; LETTER; NULLIPARA; ORAL CONTRACEPTION; POSTMENOPAUSE; PREMENOPAUSE; PRIORITY JOURNAL; PROMOTER REGION; RELATIVE; URINALYSIS;

EID: 0035804638     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/93.7.554     Document Type: Letter

References (7)

1. CYP17 promoter polymorphism and breast cancer in Australian women under age forty years
2. Molecular epidemiology of genetic polymorphisms in estrogen metabolizing enzymes in human breast cancer
3. Association between CYP17 gene polymorphism and risk of breast cancer in young women
4. Do urinary oestrogen metabolites predict breast cancer? Guernsey III cohort follow-up
5. Estrogen metabolism and risk of breast cancer: A prospective study of the 2: 16alpha-hydroxyestrone ratio in premenopausal and postmenopausal women
6. Polycystic ovaries and premature male pattern baldness are associated with one allele of the steroid metabolism gene CYP17
7. Monoclonal antibody-based enzyme immunoassay for simultaneous quantitation of 2- and 16 alpha-hydroxyestrone in urine